|
|
Article: Schering-Plough in Agreement to Market 3M Pharmaceuticals' CFC-free Albuterol Inhaler
- Article from:
- PR Newswire
- Article date:
- August 16, 1996
CopyrightCOPYRIGHT 1996 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
MADISON, N.J., and ST. PAUL, Minn., Aug. 16 /PRNewswire/ -- Schering- Plough Corporation (NYSE: SGP) and 3M Pharmaceuticals, a division of the Minnesota Mining and Manufacturing Company (NYSE: MMM), today announced an agreement under which Schering-Plough will exclusively market in the United States a proprietary 3M albuterol sulfate metered-dose inhaler (MDI) for asthma that uses a new propellant system free of any chlorofluorocarbons (CFCs). Schering-Plough, with its PROVENTIL(R) line of products, is the leading U.S. manufacturer and marketer of albuterol asthma products.
The new CFC-free albuterol MDI, which received marketing clearance from the U.S. Food and ...